- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
- Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
- Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
- Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
- Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
More ▼
Key statistics
On Wednesday, Ligand Pharmaceuticals Inc (LGND:NMQ) closed at 71.42, 45.04% above the 52 week low of 49.24 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 70.12 |
---|---|
High | 72.17 |
Low | 69.51 |
Bid | 28.57 |
Offer | 113.55 |
Previous close | 71.42 |
Average volume | 143.98k |
---|---|
Shares outstanding | 17.96m |
Free float | 17.52m |
P/E (TTM) | 24.57 |
Market cap | 1.28bn USD |
EPS (TTM) | 2.91 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼